Palbociclib + Gedatolisib for Solid Cancers
Trial Summary
What is the purpose of this trial?
This research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you must stop all current medications, but you cannot use strong CYP3A4 inhibitors/inducers, medications metabolized by UGT1A9 or CYP2D6, drugs that prolong QT interval, or proton pump inhibitors. Check with the study team for specific guidance.
What data supports the idea that Palbociclib + Gedatolisib for Solid Cancers is an effective drug?
The available research does not provide specific data on the effectiveness of Palbociclib + Gedatolisib for Solid Cancers. Instead, it focuses on another drug, Gefitinib, which has shown effectiveness in treating non-small-cell lung cancer and other solid tumors. Gefitinib has demonstrated significant efficacy, with a 75% response rate in colorectal cancer when combined with standard chemotherapy, compared to 55% with standard therapy alone. However, there is no direct information on Palbociclib + Gedatolisib in the provided research.12345
What safety data is available for the combination of Palbociclib and Gedatolisib in solid cancers?
The provided research does not contain specific safety data for the combination of Palbociclib (Ibrance) and Gedatolisib (PF-05212384) in solid cancers. The studies focus on other drugs such as Neratinib and Ibrutinib, which are not relevant to the safety profile of Palbociclib and Gedatolisib.678910
Is the drug Gedatolisib, combined with Palbociclib, a promising treatment for solid cancers?
Eligibility Criteria
Adults with advanced squamous cell lung, pancreatic, head & neck cancers or solid tumors potentially linked to PI3K-pathway changes. They must have acceptable organ function and blood counts, no severe diabetes or heart conditions, not be on certain drugs affecting liver enzymes or the heart's rhythm, and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Palbociclib orally once daily on Days 1-21 and Gedatolisib intravenously once weekly during 4-week cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Gedatolisib (PI3K/mTOR Inhibitor)
- Palbociclib (CDK4/6 Inhibitor)